WASHINGTON — Medicare has already received more than 4,300 comments on its recent proposal to limit coverage for Biogen’s controversial Alzheimer’s drug Aduhelm, and other similar drugs. But most aren’t from drugmakers, Alzheimer’s advocacy groups, or even neurologists.
They’re from two unexpected letter writing campaigns.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
